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Intestinal current measurement (ICM) in Ussing chambers is used to study the CFTR
basic defect ex vivo in human rectal biopsies. Over the past 15 years comprehensive
experience with different chamber setups and protocols (Veeze 1994, de Jonge 2004,
Mall 2004) has been made in a number of European centers. Aim of this ECFS
Diagnostic Network Working Group survey was to describe updated differences in
methodology and a comparison of results.
All participating European centers were asked to provide details about methodology,
evaluation protocol and local reference data by a standardised survey form. Original
tracings and interpretation of 5 F508del homozygous CF patients and 5 healthy
controls were collected from each center and centrally compared.
We conﬁrmed differences in the European ICM practice including two types of
Ussing chamber, the evaluation protocol, buffers, biopsy technique and readout
parameter (Isc, Vte). Qualitative differences in CFTR chloride secretion between
CF and non-CF were detected by all centers, whereas quantitative parameter mainly
differed between Isc and Vte measurements and different protocol sequences.
This ﬁrst European ICM survey provides a platform for the development of a
harmonised ICM protocol (European SOP). Reﬁnements in methodology and more
standardised measurements according to a common protocol could help to promote
the harmonisation process, and to further develop ICM as an important outcome
parameter in a multicenter network for (pre-)clinical trials aiming to correct the
CFTR basic defect.
Supported by: ECFS Diagnostic Network Working Group.
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The I-neb AAD System (I-neb device) can be operated in Tidal Breathing Mode (TBM)
or a new Target Inhalation Mode (TIM). With TBM aerosol is delivered into the ﬁrst
portion of each breath during tidal breathing. With TIM the patient is guided to breathe
in a slow, deep inhalation, which can result in shorter treatment times.
Fifty patients with cystic ﬁbrosis, FVC> 1 L using the I-neb device with colistimethate
sodium (CMS) were included in a 3-month patient handling evaluation of the I-neb
device operated in TBM and TIM. Patients were encouraged to operate the I-neb device
in TIM for the delivery of all their inhaled medication. Tobramycin and hypertonic
saline were delivered using two treatments with 0.5mL metering medication chambers
(MMC). Other drugs (CSM, salbutamol and dornase alfa) were delivered using a 0.3mL
MMC.
There were 10,234 complete treatments administered using TIM, and 1,675 adminis-
tered using TBM. The mean treatment time in TIM was 4.27 min, compared with 6.47
min in TBM. Mean treatment times for patients using TIM were divided according to
the duration of the last inhalation recorded.
Use of TIM can shorten treatment times compared with TBM, and longer last inhalation
duration equated to shorter treatment times.
Table 1. Mean treatment time per last inhalation duration
Last inhalation duration
recorded (s)
% of
TIM patients
Mean treatment
time (min)
% reduction in treatment time
compared with TBM
2 100 4.27 34
>2 80 4.21 35
>3 68 3.97 38
>5 48 3.70 43
= 8 18 3.50 46
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The transfection of cells by pDNA/cationic polymer complexes supposes that the
delivery of pDNA in the nucleus requires polyplex capture, internalization, pDNA
endosome escape and pDNA nuclear import. We have designed a new histidine-
rich polyethylenimine that allows very efﬁcient transfection with low cytotoxicity.
The polymer possess protonable amines and imidazole groups in an acidic medium
that favour pDNA endosome escape that favour pDNA endosome escape. We have
designed an extended NFúB DNA binding sequence (so called 3NF) that is strongly
recognized by NFúB upon transfection. Here, we present the quantiﬁcation of the
pDNA copies number in the nucleus of cells transfected with lPEI and histidine-rich
PEI. We found that ~1500 copies of p3NF-luc3NF versus 250 copies of 3NF-free
pDNA were imported in the nucleus upon 5 h transfection. The quantity of p3NF-
luc-3NF dropped dramatically in the presence of the BAY 11–7085, an inhibitor
of NFúB activation. These data strongly support the remarkable nuclear import of
p3NF-luc-3NF mediated by NFúB. FRET experiments revealed that most of nuclear
pDNA was still condensed with the polymer. Using cells expressing a GFP-tagged
protein of the nuclear pore complex, we visualized for the ﬁrst time in live cells
the passage of pDNA through the nuclear pore.
Supported by: Vaincre la mucoviscidose (VLM) and Association Franc¸aise contre
les Myophaties (AFM).
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Aerosol systems used for inhalation therapy should be able to deliver medication to
the region of the respiratory system where the drug is required to optimize efﬁcacy.
However, efﬁciency and reproducibility of particle deposition in the lung in most
of the commercially available aerosol systems is limited by the breathing pattern
of the patients.
The AKITA JET inhalation system was developed to guide the patient through
the inhalation using a controlled ﬂow rate and inhalation volume. In order to both
individualize breathing pattern as well as record compliance data of therapy, an
improved Smart Card technology is incorporated into the system. In most countries,
two ‘standard’ Smart Cards are enclosed to the system containing the following
medications for treatment of cystic ﬁbrosis and severe asthma diseases:
Cystic Fibrosis:
– Atrovent/Sultanol
– Tobramycine
– DNAse
– Colistin
Asthma and COPD:
– Atrovent/Sultanol
– Fluticasone
– Budesonide
The Smart Cards are programmed in a way to count down the number of breaths. A
pre-selectable inspiration time per breath and therefore a certain number of breaths
for every medication assure correct dosage and reproducible drug delivery for every
treatment.
Aerosol characterizations showed (for all medications) a particle size (MMD by
laser diffraction) of 3.76mm (GSD 1.99) and delivered dose of 41−57% of ﬁlling
dose independent from the pre-selected inspiration time per breath.
Controlled breathing reduces inhalation treatment time since lung deposition of
inspired particles is higher if compared to conventional devices where patients are
free to inhale spontaneously. AKITA JET is a highly efﬁcient nebulizer system that
ensures high and homogeneous lung deposition of different drugs.
